Press Release

Printer Friendly Version View printer-friendly version
<< Back
T2 Biosystems Chief Scientific Officer Tom Lowery to Present at BIO 2017 Convention
Panel to Discuss Use of Novel Diagnostic Technologies to Improve Patient Care and Aid in Management of Antimicrobials

LEXINGTON, Mass., June 19, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that its chief scientific officer, Tom Lowery, Ph.D. is scheduled to present at the 2017 BIO International Convention in San Diego, CA as part of a session titled “Using Novel Diagnostic Technologies to Improve Patient Care.” He will be joined by Christiane Honisch, Ph.D., director of microbiology markets for Illumina, and Jorge Villacian, M.D., chief medical officer of Janssen Diagnostics, a Johnson & Johnson subsidiary, in a panel moderated by Evelyn Ellis-Grosse, Ph.D., co-founder and chief scientific officer, of Zavante Therapeutics, Inc. The panel discussion will take place on June 20, 2017 from 1:45-2:45 p.m. PDT.

"T2 Biosystems has developed novel products that are proven to improve patient care and decrease the use of antimicrobials," said Dr. Lowery, "and we're excited to be a part of this panel to share our experience with the T2Sepsis Solution."

The panel will discuss the critical role new diagnostic technologies play in improving care of patients suffering from infection and aiding in decreasing the use of antimicrobials. The panelists will feature the importance of diagnostics, updates on United States efforts to incentivize diagnostics, and novel diagnostic technologies.

The BIO International Convention 2017 covers the biotechnology and pharma industry's most relevant and timely topics. This year’s convention includes 192 company presentations, with 800+ speakers covering 157 topics. The convention is scheduled to take place from June 19-22, 2017.

For more information on the T2Sepsis Solution™ customer experience, a webinar on the implementation and clinical impact of T2Candida® at Henry Ford Health System is available for continuing medical education credits. 

About T2 Biosystems
T2 Biosystems is dedicated to developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit

About Tom Lowery, Ph.D.
Tom Lowery, Ph.D. has served as chief scientific officer since September 2013. Since joining T2 Biosystems in February 2007, Tom has held various technical leadership roles, including leadership of assay, methods, reagents and detector development programs. By applying his extensive experience in cutting edge biochemical and biophysical methods development he has played a key role in establishing T2 Biosystems’s technical capabilities and in driving the company's product strategy and development. Prior to joining T2 Biosystems, Tom conducted research at the University of California Berkeley focused on developing innovative magnetic resonance based biosensors for molecular imaging. This work was funded by the UC Graduate Research and Education in Adaptive Biotechnology program. Tom earned his Ph.D. in chemistry from the University of California, Berkeley and graduated Summa Cum Laude with a B.S. in Biochemistry and University Honors from Brigham Young University.

Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer

Media Contact:
Matthew McKillip, T2 Biosystems

Investor Contact:
Tucker Elcock, Teneo Strategy

Primary Logo

T2 Biosystems, Inc.